CAR T cell therapy in China has emerged as a leading-edge treatment for certain types of cancer, particularly hematologic malignancies like lymphoma and leukemia. The cost of CAR T cell therapy in China is generally lower compared to Western countries, reflecting both the country's rapidly growing biotech industry and its different economic landscape.